<DOC>
	<DOCNO>NCT02640677</DOCNO>
	<brief_summary>4CMenB approve Food Drug Administration ( FDA ) United States January 2015 people age 10 25 year age . 4CMenB used pregnancy clearly need sometimes , inadvertent exposure pregnancy may also occur - woman know pregnant , example . The objective study evaluate safety 4CMenB pregnancy help u learn health woman vaccinate 4CMenB within 30 day prior last menstrual period ( LMP ) time pregnancy , health infant . Pregnant woman within US receive least 1 dose 4CMenB vaccine within 30 day prior last menstrual period time pregnancy eligible participate . A woman may self-enroll registry call pregnancy registry telephone number directly healthcare provider ( HCP ) , consent , enroll behalf . Alternatively HCPs may report anonymous data pregnancy exposure outcomes occur within network/health maintenance organization ( HMO ) . The health woman infant follow end pregnancy .</brief_summary>
	<brief_title>Safety 4CMenB Exposure During Pregnancy</brief_title>
	<detailed_description />
	<criteria>Any pregnant woman within US receive least 1 dose 4CMenB vaccine within 30 day prior LMP time pregnancy : Sufficient evidence confirm exposure meningococcal B vaccine ( confirm possible 4CMenB exposure ) occur within 30 day prior LMP time pregnancy Sufficient information determine whether pregnancy prospectively retrospectively register ( i.e. , whether outcome pregnancy know time first contact registry ) Date pregnancy exposure register Full reporter ( i.e. , HCP ) contact information allow followup ( name , address , etc . ) Pregnant woman vaccinate different brand Meningococcal B vaccine include . ( Of note : In event ascertain meningococcal B vaccine woman expose , unknown exposure cohort establish analyzed separately ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>